
Novalis LifeSciences is a boutique investment and advisory firm for the life sciences industry, founded in 2017 by Marijn E. Dekkers. The firm invests in small to medium-size life science companies across life science tools, diagnostics, and biopharma therapeutics.
70% of their portfolio is in Biotech & Life Sciences. They made 1 investment in the last 12 months. Average disclosed round size is $56.7M (across 19 rounds with reported amounts).
Portfolio
17
Fund Size
$300M
Top Stage
Series B
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
23 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Series B | $27.5M | Dec 2025 | |
| Seed | $18M | Sep 2023 | |
| MMercy Bio | Series A | $41M | Apr 2023 |
| Series A | $41M | Apr 2023 | |
| Unknown | — | Aug 2022 | |
| Unknown | — | Aug 2022 | |
| Series C | $70M | Jul 2022 | |
| Series C | $85.2M | Jun 2022 | |
| Series B | $80M | Mar 2022 | |
| Series B | $100M | Jan 2022 | |
| Series B | $34M | Jan 2022 | |
| Series D | $116M | Sep 2021 | |
| Series B | $37M | Apr 2021 | |
| Series D | $116M | Jan 2021 | |
| Series B | $45M | Jun 2020 | |
| Series B | — | Jun 2020 | |
| Growth | $34M | Jan 2020 | |
| Series C | — | Jan 2019 | |
| Series C | $27M | Jul 2017 | |
| Series B | $80M | — | |
| Unknown | $21M | — | |
| Series C | $70M | — | |
| Growth | $34M | — |
Top Co-Investors
Northpond Ventures6 shared
PMV4 shared
iSelect Fund3 shared
Finistere Ventures3 shared
Romulus Capital3 shared
Omega Funds3 shared
Fund+3 shared
Catalio Capital Management2 shared
Illumina Ventures2 shared
Germin8 Ventures2 shared
Endeavor2 shared
Bill & Melinda Gates Foundation2 shared
Blue Horizon2 shared
Tao Capital Partners2 shared
ARCH Venture Partners2 shared
ID8 Investments2 shared
Labcorp2 shared
Sozo Ventures2 shared
Broadway Angels2 shared
Bridge Bank2 shared
Last updated: 7 October 2026